Skip to main content

Table 2 Distribution of patients’ treatment in relation to expression of VEGFR-3 or CXCR4

From: VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Characteristic

FLO

 

FLP

 
 

n

%

n

%

VEGFR-3 +

22

56.4

17

43.6

VEGFR-3 -

14

46.7

16

53.3

CXCR4 +

13

50

13

50

CXCR4 -

24

54.5

20

45.5

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us